Does insurance cover Mounjaro in Texas?

If you’re considering a GLP-1 medication like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, one of your first questions is probably: Will my insurance cover this? The answer isn’t always straightforward. These breakthrough medications can cost over $1,000 a month without coverage, making insurance approval critical for most people.

In this guide, we’ll break down exactly how insurance coverage works for these popular GLP-1 drugs, what criteria you need to meet, common reasons for denials, and what to do if your claim gets rejected. We’ll also explore self-pay options and telehealth access—because getting the treatment you need shouldn’t feel impossible.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into insurance coverage, it’s helpful to understand what each medication is designed to do:

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or those who are overweight (BMI ≥27) with at least one weight-related health condition like high blood pressure or type 2 diabetes.

Ozempic (also semaglutide) is approved for treating type 2 diabetes, not weight loss. However, weight loss is a common side effect, which has led many people to use it off-label for obesity—something most insurers explicitly won’t cover.

Mounjaro (tirzepatide) is another diabetes medication that’s shown remarkable weight-loss results. Like Ozempic, it’s approved for type 2 diabetes, though Eli Lilly markets a separate weight-loss version called Zepbound.

The FDA indication matters enormously for insurance coverage. Insurers generally cover medications only for their approved uses, which is why getting Ozempic covered for weight loss alone is nearly impossible, while Wegovy—approved for obesity—has a better (though still challenging) path to coverage.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect

Coverage for Weight Loss (Wegovy)

If you have private health insurance through your employer or the marketplace, Wegovy coverage is far from guaranteed. Many commercial plans consider anti-obesity medications ‘optional’ benefits and simply exclude them from coverage due to high costs.

According to a 2024 analysis, a significant number of employer-sponsored plans don’t cover weight-loss drugs at all. Those that do cover Wegovy typically require strict prior authorization, meaning your doctor must prove medical necessity before insurance will approve the prescription.

Typical coverage criteria include:

• BMI requirement: Most plans require a BMI of 30 or higher (obesity), or 27 or higher with at least one obesity-related condition like diabetes, hypertension, or sleep apnea
• Documented lifestyle efforts: You’ll usually need to show at least 6 months of supervised diet and exercise attempts that didn’t achieve sufficient weight loss
• Age restrictions: Generally limited to adults 18 and older (some plans extend to adolescents 12+ with severe obesity)
• Ongoing monitoring: Coverage often continues only if you achieve meaningful weight loss (typically 5% or more of body weight) within the first 3-6 months

Even with approval, Wegovy is typically placed in Tier 3 or 4 on formularies—meaning higher copays or coinsurance, often 25-40% of the drug’s cost.

Coverage for Diabetes (Ozempic and Mounjaro)

Commercial insurance coverage is much more reliable when these drugs are prescribed for their FDA-approved use: type 2 diabetes.

Ozempic is widely covered on most commercial plans for diabetes management. You’ll likely need prior authorization confirming your type 2 diabetes diagnosis, and many plans require that you’ve tried first-line treatments like metformin before moving to a GLP-1.

Mounjaro follows similar patterns. As a newer medication, it often faces stricter step therapy requirements—insurers may ask you to try Ozempic or another older GLP-1 before approving Mounjaro, given its higher cost.

Both medications typically land in Tier 3 (non-preferred brand) or sometimes a specialty tier, with monthly copays ranging from $50 to several hundred dollars depending on your plan.

Important note: If you have diabetes and are prescribed these medications, your insurer will cover them for diabetes management. However, if you’re trying to get Ozempic or Mounjaro covered solely for weight loss without a diabetes diagnosis, expect a denial. Insurers have tightened policies to prevent off-label weight-loss use of diabetes drugs.

Medicare Coverage: Limited and Specific

Medicare’s coverage of GLP-1 medications remains restrictive, primarily because federal law prohibits Medicare Part D from covering drugs used for weight loss or weight gain.

Traditional Medicare Part D

Under standard Part D plans:

• Ozempic and Mounjaro are covered when prescribed for type 2 diabetes, treated similarly to other diabetes medications
• Wegovy is generally not covered for weight loss alone

There’s one important exception: In 2024, Medicare began covering Wegovy for patients with established cardiovascular disease who need it to reduce their risk of heart attack and stroke—not primarily for weight loss. This narrow cardiovascular indication allows some Medicare beneficiaries to access Wegovy, but only if they meet specific clinical criteria.

Medicare Advantage

Some Medicare Advantage plans have started offering limited coverage for anti-obesity medications in 2025, but availability varies significantly by plan. If obesity medication coverage is important to you, review plan formularies carefully during open enrollment.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss medications is extremely variable because states have flexibility in deciding whether to cover drugs for obesity treatment.

As of late 2024, only about 13 states covered GLP-1s for weight loss through Medicaid—and several of those states are now reversing course due to budget concerns.

States Cutting or Restricting Coverage

California: Medi-Cal covered Wegovy with prior authorization through 2025, but the state announced it will eliminate coverage for all weight-loss GLP-1s on January 1, 2026, citing budgetary constraints. The only exception will be for pediatric patients under EPSDT (Early and Periodic Screening, Diagnostic and Treatment) protections.

Pennsylvania: After adding coverage in 2023-2024 with strict prior authorization requirements, Pennsylvania Medicaid will stop covering Wegovy and other obesity medications in January 2026 due to cost pressures.

States with No Coverage

Texas: Texas Medicaid explicitly excludes all obesity medications for adults over 21. The state’s Vendor Drug Program does not cover Wegovy, Saxenda, or any weight-loss drugs, citing the federal optional exclusion for anti-obesity treatments.

Florida: Similar to Texas, Florida Medicaid does not cover weight-loss medications, utilizing the federal law that makes obesity drug coverage optional.

Illinois: Despite expanding coverage for state employees, Illinois Medicaid does not cover anti-obesity medications as of 2025.

States Still Offering Coverage (with Restrictions)

New York: New York’s Medicaid program covers Wegovy with prior authorization. Requirements include documented BMI ≥30 (or ≥27 with comorbidities), evidence of lifestyle modification attempts, and ongoing monitoring for effectiveness.

States that do cover these medications almost universally require:

• Prior authorization with detailed medical documentation
• BMI thresholds (typically ≥30 or ≥27 with comorbidities)
• Proof of at least 6 months of supervised weight-loss attempts
• Regular follow-up to demonstrate continued effectiveness
• Quantity limits (usually 4 pens per 28 days)

Even in states with coverage, the approval process can be lengthy and documentation-intensive.

Common Reasons for Insurance Denials

Understanding why claims get denied can help you avoid pitfalls and strengthen your initial request.

1. Not Meeting Medical Necessity Criteria

The most frequent denial reason is failing to meet the insurer’s specific requirements. This might mean:

• Your documented BMI falls below the threshold (often 30, or 27 with comorbidities)
• You don’t have a qualifying weight-related health condition when one is required
• Your weight-loss goals don’t align with clinical guidelines

2. Insufficient Documentation of Prior Attempts

Nearly all insurers require evidence that you’ve tried—and not succeeded with—lifestyle modifications before approving expensive GLP-1 medications. Denials often stem from:

• No record of a supervised diet and exercise program
• Insufficient duration (less than 6 months documented)
• Missing documentation from healthcare providers

Your doctor needs to provide detailed notes showing you participated in a structured weight-loss program with regular monitoring.

3. Step Therapy Requirements Not Met

For diabetes medications, insurers often require step therapy—trying cheaper medications first. Common step therapy requirements include:

• For Ozempic: Must have tried metformin or another first-line diabetes medication unless contraindicated
• For Mounjaro: May need to try Ozempic or another GLP-1 before approval
• For Wegovy: Some plans require trying older weight-loss medications like phentermine or orlistat first

4. Off-Label Use

Insurers will deny coverage if you’re trying to use a diabetes medication solely for weight loss. For example:

• Requesting Ozempic when you don’t have type 2 diabetes
• Requesting Mounjaro for obesity (when Zepbound is the approved weight-loss version)

Off-label prescribing is common in medicine, but insurers rarely cover it for these high-cost medications.

5. Plan Exclusions

Some insurance plans—particularly employer-sponsored plans—explicitly exclude all weight-loss medications from coverage. These exclusions are written into the policy, and no amount of medical justification will overturn them.

If your plan has a blanket exclusion, you’ll need to explore self-pay options or wait until your next open enrollment period to switch to a plan that covers obesity treatment.

How to Navigate Prior Authorization Successfully

Prior authorization can feel like a hurdle, but being prepared significantly improves your chances of approval.

Gather Complete Documentation

Work with your healthcare provider to compile:

• Current and historical BMI measurements (ideally from multiple visits)
• Medical records showing obesity-related conditions (diabetes, hypertension, sleep apnea, etc.)
• Documentation of supervised weight-loss programs including dates, interventions tried, and outcomes
• Prescription history showing you’ve tried other medications if required by step therapy
• Letter of medical necessity from your doctor explaining why this specific medication is appropriate for you

Submit a Detailed Request

Your doctor’s office will typically handle the prior authorization, but you should:

• Confirm all required information is included
• Ask for a copy of the submitted documentation
• Get the reference number and expected timeline for response
• Request your provider mark it ‘urgent’ if medically appropriate

Most insurers respond to prior authorization requests within 5-7 business days, though complex cases may take up to 15 days.

What If You’re Denied?

If your initial request is denied, don’t give up. You have the right to appeal, and many denials are overturned when additional information is provided.

Steps for a successful appeal:

1. Request the denial letter in writing with specific reasons for denial
2. Review your plan’s appeal process and deadlines (typically 180 days)
3. Work with your doctor to address each denial reason with additional documentation
4. Provide peer-reviewed studies supporting GLP-1 effectiveness for your specific situation
5. Consider escalating to an external review if your internal appeal is denied

Success rates for appeals vary by insurer, but cases where you truly meet criteria but documentation was incomplete often succeed on appeal. Persistence matters—some patients report approval after a second or even third appeal.

Understanding Coverage Through Klarity Health

At Klarity Health, we understand that navigating insurance for GLP-1 medications can be overwhelming. Our telehealth platform connects you with licensed healthcare providers who can evaluate whether these medications are right for you and help with the documentation needed for insurance approval.

We accept both insurance and cash-pay options, giving you flexibility regardless of your coverage status. Our providers have experience working with various insurance companies and understand their specific requirements, which can streamline the prior authorization process.

With transparent pricing and providers available across the country, Klarity Health makes accessing GLP-1 medications more straightforward—whether you’re working through insurance or exploring self-pay options.

Self-Pay Options: Affording GLP-1s Without Insurance

If insurance won’t cover your medication, or if you’re uninsured, the list prices can be daunting—often $1,000-$1,350 per month. Fortunately, several programs have emerged to make these medications more accessible.

GoodRx Weight Loss Program

In November 2025, GoodRx launched a groundbreaking partnership with Novo Nordisk offering:

• $199 per month for your first two months of Wegovy or Ozempic
• $349 per month ongoing for most doses
• Available at nearly all pharmacies nationwide

This represents a 60-70% discount off list prices and has made self-pay far more feasible for many patients.

Manufacturer Savings Programs

Novo Nordisk offers several programs:

• Savings Card (Wegovy): If you have commercial insurance that covers Wegovy, you may pay as little as $0-$25 per month (the card covers up to $225 of your copay)
• Wegovy Access Program: Self-pay patients can access Wegovy for $349/month directly through Novo
• Patient Assistance Program: Free medication for uninsured individuals meeting income requirements (typically up to 400% of federal poverty level)

Eli Lilly offers:

• Savings Card (Mounjaro): Reduces copays to $25/month for commercially insured patients with type 2 diabetes
• Zepbound Self-Pay: Single-dose vials now available for $299-$449 depending on dose strength (down from $499)
• Patient Assistance Program: Free Mounjaro for qualifying low-income patients

Important limitation: Manufacturer copay cards cannot be used with government insurance (Medicare, Medicaid) but work with most private plans.

Considerations for Compounded Versions

Some telehealth services and wellness clinics offer compounded semaglutide or tirzepatide at lower prices than brand-name versions. While these may cost $200-400 monthly, it’s crucial to understand:

• They are not FDA-approved products
• Quality and safety can vary significantly between compounding pharmacies
• Efficacy may differ from the branded medications used in clinical trials
• The FDA has issued warnings about compounded GLP-1s

If you’re considering a compounded option, discuss it thoroughly with your healthcare provider and only use reputable, licensed compounding pharmacies.

Telehealth and Insurance: What You Need to Know

The good news is that telehealth coverage for weight management and diabetes care has become standard across most insurance plans.

Telehealth Parity Laws

More than 40 states have enacted telehealth parity laws requiring private insurers to cover virtual visits the same as in-person appointments. Since the COVID-19 pandemic, Medicare and most Medicaid programs have also expanded telehealth coverage permanently.

This means:

• Your insurance likely covers telehealth visits for weight management counseling and medication management
• Copays are typically the same as in-person visits with the same provider type
• Nutritional counseling for obesity is an ACA-mandated preventive service, often covered at 100% via telehealth
• Follow-up medication management can be done virtually in most cases

Verifying Coverage

Before scheduling a telehealth appointment:

• Check if the provider or platform is in-network with your insurance
• Confirm your plan covers telehealth for the specific service (most do, but some limitations exist)
• Understand your copay or coinsurance for the visit
• Ask whether the prescription will be covered separately under your pharmacy benefit

At Klarity Health, we’re transparent about costs upfront. While our visit fees are cash-pay for many services, any prescription we write can be filled through your insurance pharmacy benefit—helping you access medications at covered rates even if the consultation itself is out-of-pocket.

A State-by-State Snapshot: Where Does Your State Stand?

Coverage varies dramatically depending on where you live. Here’s a quick reference for our priority states:

California: Medi-Cal will end all weight-loss GLP-1 coverage January 1, 2026. Commercial plans vary widely—check your specific employer plan.

Texas: Texas Medicaid doesn’t cover obesity medications. Commercial coverage available but often with strict prior authorization.

Florida: No Florida Medicaid coverage. Commercial plans follow national trends with limited weight-loss drug coverage.

New York: New York Medicaid covers Wegovy with strict PA requirements. Commercial plans typically offer coverage with prior auth.

Pennsylvania: PA Medicaid discontinuing coverage January 2026. Commercial insurance varies by plan—many large employers offer limited coverage.

Illinois: Illinois Medicaid doesn’t cover obesity drugs. State employee plans do cover them, but commercial/marketplace coverage is plan-specific.

If your state Medicaid doesn’t cover GLP-1s and you have commercial insurance, your path to coverage depends entirely on your specific plan’s formulary and whether your employer opted to include obesity medications.

Making the Best Decision for Your Situation

Accessing GLP-1 medications for weight loss or diabetes management in 2025 often requires persistence, patience, and a clear understanding of your coverage options.

If you have commercial insurance:

• Review your formulary to see if your medication is covered
• Gather all required documentation before submitting prior authorization
• Be prepared to appeal if initially denied
• Consider manufacturer savings cards to reduce out-of-pocket costs

If you have Medicare:

• Understand that weight-loss coverage is extremely limited
• Diabetes-indicated GLP-1s are covered for diabetes management
• Look into Medicare Advantage plans during open enrollment if obesity medication coverage is important

If you have Medicaid:

• Check your specific state’s coverage policies
• Be aware of changing policies (many states cutting coverage in 2026)
• Pediatric patients may have different coverage under EPSDT

If you’re uninsured or denied:

• Explore GoodRx’s discounted pricing programs
• Apply for manufacturer patient assistance programs
• Consider all your weight-loss options, including older, less expensive medications
• Work with telehealth providers like Klarity Health who offer cash-pay pricing and can help you find the most affordable path

Frequently Asked Questions

Q: Can I use Ozempic for weight loss if I don’t have diabetes?

A: While Ozempic is sometimes prescribed off-label for weight loss, insurance almost never covers it for this use. You would need to pay out-of-pocket. Wegovy (the same medication, different dosing) is FDA-approved for weight loss and has a better chance of insurance coverage.

Q: How long does prior authorization take?

A: Most insurers respond within 5-7 business days for routine requests. Urgent requests may be processed faster (24-72 hours), while appeals can take 15-30 days.

Q: Will my insurance cover these medications long-term?

A: If approved, coverage typically continues as long as you’re meeting the insurer’s effectiveness requirements (usually at least 5% weight loss or A1c improvement) and attending regular follow-ups. Many plans require periodic reauthorization, often every 6-12 months.

Q: What’s the difference between the savings card and patient assistance program?

A: Savings cards reduce your copay if you have commercial insurance covering the medication. Patient assistance programs provide free medication if you’re uninsured or underinsured and meet income requirements. You typically can’t use both simultaneously.

Q: Are there generic versions of these medications?

A: No. All GLP-1 medications (Wegovy, Ozempic, Mounjaro, Zepbound) are currently brand-only. Patents extend into the 2030s, meaning generic versions won’t be available for several more years.

Take the Next Step

Whether you’re navigating insurance approval or exploring self-pay options, accessing effective weight-loss or diabetes medication doesn’t have to be an impossible journey.

At Klarity Health, our providers are ready to evaluate your individual situation, help determine if GLP-1 medications are appropriate for you, and guide you through the insurance process or connect you with affordable self-pay options. With providers available across the country and both insurance and cash-pay options, we’re here to make your path to treatment as straightforward as possible.

Ready to explore your options? Connect with a Klarity Health provider today to discuss whether Wegovy, Ozempic, Mounjaro, or other weight-management medications might be right for you—and get clear answers about coverage and costs upfront.

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

Top 5 Citations:

1. California Department of Health Care Services (DHCS) – Medi-Cal Coverage Changes for GLP-1 Weight Loss Medications. California Medical Association News. December 2025. www.cmadocs.org

2. Cohen, J. ‘Coverage of Weight Loss Drugs by Medicaid Plans Continues to Lag.’ Forbes Healthcare. August 7, 2025. www.forbes.com

3. Kaiser Family Foundation (KFF). ‘Medicaid Coverage of and Spending on GLP-1s.’ KFF Issue Brief. November 4, 2024. www.kff.org

4. GoodRx. ‘GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription; Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic and Wegovy.’ Business Wire Press Release. November 17, 2025. www.businesswire.com

5. Aetna Clinical Policy Bulletin – Weight Loss (BMI ≥35) GIP-GLP-1/GLP-1 Agonists Prior Authorization Criteria. May 2024. www.aetna.com

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499